Laboratorios Farmaceuticos ROVI SA (ROVI.MC)
ROVI.MC on Madrid SE C.A.T.S.
17.15EUR
20 Apr 2018
17.15EUR
20 Apr 2018
Change (% chg)
€-0.15 (-0.87%)
€-0.15 (-0.87%)
Prev Close
€17.30
€17.30
Open
€17.05
€17.05
Day's High
€17.20
€17.20
Day's Low
€17.05
€17.05
Volume
1,045
1,045
Avg. Vol
5,622
5,622
52-wk High
€18.75
€18.75
52-wk Low
€14.20
€14.20
About
Laboratorios Farmaceuticos ROVI SA (ROVI) is a Spain-based company principally engaged in the pharmaceutical industry. The Company’s main activities include the development and commercialization, nationwide and abroad, of medicines and drugs. Its products are structured into three fields: Diagnostic, which offers contrast... (more)
Overall
| Beta: | 0.51 |
| Market Cap(Mil.): | €860.00 |
| Shares Outstanding(Mil.): | 50.00 |
| Dividend: | 0.12 |
| Yield (%): | 1.06 |
Financials
| ROVI.MC | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 49.18 | 31.01 | 33.60 |
| EPS (TTM): | 0.35 | -- | -- |
| ROI: | 7.90 | 13.60 | 13.19 |
| ROE: | 9.19 | 15.26 | 15.00 |
BRIEF-Rovi Sees 2018 Operating Revenue Growth At Mid-Single-Digit Rate
Feb 20 Laboratorios Farmaceuticos ROVI SA (ROVI) :
BRIEF-ROVI FY Net Profit Down At 17.2 Mln Euros
Feb 20 LABORATORIOS FARMACEUTICOS ROVI SA (ROVI) :
BRIEF-Rovi Gets 45 Million Euro Loan From European Investment Bank
* GETS 45 MILLION EURO LOAN FROM EUROPEAN INVESTMENT BANK Source text for Eikon: Further company coverage: (Gdynia Newsroom)
BRIEF-Rovi 9-month operating revenue up 6 pct at 203.4 mln euros YoY
* RECURRENT NET PROFIT DECREASED BY 4 PERCENT TO 17.0 MILLION EUROS IN 9-MONTH
BRIEF-Rovi announces update on risperidone project
* ANNOUNCES UPDATE ON A PHASE III STUDY FOR A LONG-ACTING INJECTABLE (LAI) TO TREAT SCHIZOPHRENIA CALLED DORIA(PREVIOUSLY RISPERIDONE ISM)
Estimates